Covalon has added five medical industry sales, business development and marketing staff and redeployed internal staff to sales and marketing roles.
In addition, the company is also working on the introduction of new technologies and formulations for Covalon’s existing channel and direct to consumers.
Covalon has reported a revenue of $1,011,436 for the second quarter ended 31 March 2011.
Net loss was $430,610 or $0.006 per share.
